WO2023039064A3 - Broadly neutralizing antibodies against sars-like viruses - Google Patents

Broadly neutralizing antibodies against sars-like viruses Download PDF

Info

Publication number
WO2023039064A3
WO2023039064A3 PCT/US2022/042906 US2022042906W WO2023039064A3 WO 2023039064 A3 WO2023039064 A3 WO 2023039064A3 US 2022042906 W US2022042906 W US 2022042906W WO 2023039064 A3 WO2023039064 A3 WO 2023039064A3
Authority
WO
WIPO (PCT)
Prior art keywords
viruses
antibodies
broadly neutralizing
neutralizing antibodies
antibodies against
Prior art date
Application number
PCT/US2022/042906
Other languages
French (fr)
Other versions
WO2023039064A2 (en
Inventor
Wanting HE
Rami MUSHARRAFIEH
Ge Song
Katharina DUEKER
Thomas Rogers
Dennis Burton
Raiees Andrabi
Original Assignee
The Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Scripps Research Institute filed Critical The Scripps Research Institute
Publication of WO2023039064A2 publication Critical patent/WO2023039064A2/en
Publication of WO2023039064A3 publication Critical patent/WO2023039064A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The invention provides novel broadly neutralizing antibodies and related antibody agents against SARS like viruses, e.g., human coronaviruses. Also provided in the invention are polynucleotides and vectors encoding such antibodies, as well as pharmaceutical compositions containing the antibodies or polynucleotides. Therapeutic uses of the antibodies or pharmaceutical compositions in preventing or treating viral infections (e.g., SARS-CoV-2 infection) are also encompassed by the invention.
PCT/US2022/042906 2021-09-08 2022-09-08 Broadly neutralizing antibodies against sars-like viruses WO2023039064A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163241590P 2021-09-08 2021-09-08
US63/241,590 2021-09-08

Publications (2)

Publication Number Publication Date
WO2023039064A2 WO2023039064A2 (en) 2023-03-16
WO2023039064A3 true WO2023039064A3 (en) 2023-08-31

Family

ID=85507086

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/042906 WO2023039064A2 (en) 2021-09-08 2022-09-08 Broadly neutralizing antibodies against sars-like viruses

Country Status (1)

Country Link
WO (1) WO2023039064A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030157109A1 (en) * 2002-01-07 2003-08-21 Corvalan Jose R. F. Antibodies directed to PDGFD and uses thereof
US20080248043A1 (en) * 2006-05-19 2008-10-09 Amgen Inc. Antibodies to SARS coronavirus
WO2021021605A1 (en) * 2019-07-26 2021-02-04 Vanderbilt University Human monoclonal antibodies to enterovirus d68

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030157109A1 (en) * 2002-01-07 2003-08-21 Corvalan Jose R. F. Antibodies directed to PDGFD and uses thereof
US20080248043A1 (en) * 2006-05-19 2008-10-09 Amgen Inc. Antibodies to SARS coronavirus
WO2021021605A1 (en) * 2019-07-26 2021-02-04 Vanderbilt University Human monoclonal antibodies to enterovirus d68

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROGERS THOMAS F., ZHAO FANGZHU, HUANG DELI, BEUTLER NATHAN, BURNS ALISON, HE WAN-TING, LIMBO OLIVER, SMITH CHLOE, SONG GE, WOEHL J: "Supplemental material: Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, vol. 369, no. 6506, 15 June 2020 (2020-06-15), US , pages 956 - 963, XP055859501, ISSN: 0036-8075, DOI: 10.1126/science.abc7520 *

Also Published As

Publication number Publication date
WO2023039064A2 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
PH12018501962A1 (en) Stablizied soluble pre-fusion rsv f proteins
MX2022016405A (en) 1'-cyano nucleoside analogs and uses thereof.
MX2021005607A (en) Stabilized pre-fusion rsv f proteins.
CR20230100A (en) Phospholipid compounds and uses thereof
WO2021212049A3 (en) Anti-sars-cov-2 monoclonal antibodies
WO2021234160A3 (en) Ace2-fc fusion proteins and uses thereof
WO2021207433A3 (en) Epitopes of sars-cov-2 neutralizing antibodies
WO2019032936A8 (en) Lincosamide antibiotics and uses thereof
CR20230164A (en) Phospholipid compounds and uses thereof
ATE475408T1 (en) FORMULATIONS OF TIPIFARNIB FOR INTRAVENOUS ADMINISTRATION
MX2023004933A (en) Ace2 fusion proteins and uses thereof.
WO2022023566A3 (en) Cd-3 antibodies for the treatment of coronavirus
WO2018170236A9 (en) Cdpk1 inhibitors, compositions and methods related thereto
WO2023039064A3 (en) Broadly neutralizing antibodies against sars-like viruses
MX2022004912A (en) Novel substituted condensed ring compound.
BR112022000417A2 (en) Fusion toxin proteins for treatment of diseases related to CMV infections
WO2005032453A3 (en) Antiviral agents for the treatment, control and prevention of infections by coronaviruses
ZA202202180B (en) Engineered hcv e2 immunogens and related vaccine compositions
WO2021226037A8 (en) Treatment of viral infections
WO2023168195A3 (en) Human broadly neutralizing antibodies against betacoronaviruses
BRPI0410967A (en) compounds, compositions and their uses for the treatment of virus infections of the family flaviviridae
WO2021178960A3 (en) Compositions and methods for treatment of cancer
MX2022008036A (en) New use of bcg immunogenic formulation expressing a respiratory syncitial virus protein against hmpv.
MXPA03010829A (en) Use of polyclonal immunoglobulins.
WO2022035739A3 (en) Compositions and methods related to ebola virusvaccines

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22868056

Country of ref document: EP

Kind code of ref document: A2